• Explore /
  • Poster
  • / FDA pooled analysis of overall survival according to depth of response as a continuous variable in frontline advanced immuno-oncology renal cell carcinoma trials.

FDA pooled analysis of overall survival according to depth of response as a continuous variable in frontline advanced immuno-oncology renal cell carcinoma trials.

Abstract Poster

Authors

Elaine Chang

Elaine Chang

US Food and Drug Administration, Silver Spring, MD

Elaine Chang , Haley Gittleman , Chi Song , Erik Bloomquist , Chana Weinstock , Sundeep Agrawal , Rajeshwari Sridhara , Nicole Gormley , Laleh Amiri-Kordestani , Shenghui Tang , Daniel L. Suzman , Richard Pazdur , Paul Gustav Kluetz , David F. McDermott , Meredith M. Regan , Brian I. Rini

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2024 ASCO Genitourinary Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session C: Renal Cell Cancer; Adrenal, Penile, and Testicular Cancers

Track

Renal Cell Cancer,Adrenal Cancer,Penile Cancer,Testicular Cancer

Sub Track

Therapeutics

Citation

J Clin Oncol 42, 2024 (suppl 4; abstr 418)

DOI

10.1200/JCO.2024.42.4_suppl.418

Abstract #

418

Poster Bd #

G21

Abstract Disclosures

Similar Posters

Poster

2022 ASCO Genitourinary Cancers Symposium

Assessing physician prescribing behaviors in first-line (1L) advanced renal cell carcinoma (aRCC): A case-based study.

Assessing physician prescribing behaviors in first-line (1L) advanced renal cell carcinoma (aRCC): A case-based study.

First Author: Ajeet Gajra

First Author: Stephen Huo

First Author: Lucia Carril-Ajuria

First Author: Nizar M. Tannir